At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 140 enrolled
Drug / intervention
Nestorone gel +1 moredrug
Likely dose
Nestorone gel 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men
In Brief
A Phase 1 clinical trial evaluating Nestorone gel and Testosterone Gel for Contraception. Completed, enrolled 140 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedSep 2005
Primary CompletionJan 2007
TodayJul 2026
First PostedSep 29, 2005
Enrollment StartSep 1, 2005
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.8 years ago
Interventions
Nestorone geldrug
2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
Testosterone Geldrug
100 mg Testosterone gel daily for 3 weeks